Literature DB >> 6100611

Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.

C I Johnston, B Jackson, B McGrath, G Matthews, L Arnolda.   

Abstract

In hypertensive patients the time courses for the rise in serum MK-422 level, and fall in both angiotensin converting enzyme (ACE) activity and blood pressure after 10 mg of enalapril were very similar. A close relationship between serum MK-422 levels and percentage ACE inhibition could be demonstrated and the acute fall in blood pressure showed a good correlation with either measurement. With chronic administration, serum MK-422 levels increased linearly with the dose of enalapril. As in the acute study, close relationships between the serum MK-422 level and ACE inhibition, and between either measurement and the fall in blood pressure, could be demonstrated after chronic enalapril administration. However, when compared to the acute response, the ACE inhibition dose-response line was shifted to the right after chronic enalapril therapy suggesting that enalapril may lead to ACE induction in humans. This did not appear to influence significantly the blood pressure lowering effect of enalapril or the relationship between ACE inhibition and the hypotensive effect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6100611

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  15 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

2.  Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects.

Authors:  G P Todd; I G Chadwick; K S Higgins; W W Yeo; P R Jackson; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

4.  Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.

Authors:  R O Böhm; M A van Baak; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 6.  Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

7.  Evaluation of the safety of enalapril in the treatment of heart failure in the very old.

Authors:  C J O'Neill; S G Bowes; C M Sullens; J P Royston; W B Hunt; M J Denham; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patients.

Authors:  C J O'Neill; A Charlett; R J Dobbs; A A Deshmukh; S G Bowes; C Weller; P W Nicholson; J S Milledge; S M Dobbs
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

9.  Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.

Authors:  C I Johnston; B J Jackson; I Larmour; R Cubella; D Casley
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 10.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.